Presented at #ISNWCN:
Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy. Full phase 3 APPLAUSE-IgAN trial results: https://t.co/RD5a9ILL7X
@ISNWCN